TNNT2 and Stroke: In fact, within the intermediate-risk group, no events occurred in patients with hs-cTnT < 5 ng/L, whereas the event rate for the composite outcome (stroke, MI, and all-cause mortality) increased to 5.0% in those with hs-cTnT between 5–14 ng/L and reached 17.5% in those with hs-cTnT > 14 ng/L, showing a clear, step wise increase in adverse outcomes.